Pasar al contenido principal

MEJORA DE LAS PROPIEDADES BIOQUIMICAS DE RETROTRANSCRIPTASAS DEL VIH, UTILES EN APLICACIONES BIOTECNOLOGICAS

PID2019-104176RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Analysis and Molecular Determinants of HIV RNase H Cleavage Specificity at the PPT/U3 Junction

  • Álvarez, Mar
  • Sapena-Ventura, Enrique
  • Luczkowiak, Joanna
  • Martín-Alonso, Samara
  • Menéndez-Arias, Luis
© 2021 by the authors., HIV reverse transcriptases (RTs) convert viral genomic RNA into double-stranded DNA. During reverse transcription, polypurine tracts (PPTs) resilient to RNase H cleavage are used as primers for plus-strand DNA synthesis. Nonnucleoside RT inhibitors (NNRTIs) can interfere with the initiation of plus-strand DNA synthesis by enhancing PPT removal, while HIV RT connection subdomain mutations N348I and N348I/T369I mitigate this effect by altering RNase H cleavage specificity. Now, we demonstrate that among approved nonnucleoside RT inhibitors (NNRTIs), nevirapine and doravirine show the largest effects. The combination N348I/T369I in HIV-1BH10 RT has a dominant effect on the RNase H cleavage specificity at the PPT/U3 site. Biochemical studies showed that wild-type HIV-1 and HIV-2 RTs were able to process efficiently and accurately all tested HIV PPT sequences. However, the cleavage accuracy at the PPT/U3 junction shown by the HIV-2EHO RT was further improved after substituting the sequence YQEPFKNLKT of HIV-1BH10 RT (positions 342–351) for the equivalent residues of the HIV-2 enzyme (HQGDKILKV). Our results highlight the role of β-sheets 17 and 18 and their connecting loop (residues 342–350) in the connection subdomain of the large subunit, in determining the RNase H cleavage window of HIV RTs., This research was funded by the Spanish Ministry of Science and Innovation (grants BIO2016-76716-R (AEI/FEDER, UE), and PID2019-104176RB-I00/AEI/10.13039/501100011033), and an institutional grant of Fundación Ramón Areces (Madrid, Spain) to the CBMSO. J.L. was a postdoctoral fellow of the Juan de la Cierva program, funded by the Spanish Ministry of Economy and Competitiveness (grant FJCI-2015-23564). S.M.-A. is a predoctoral fellow of the Spanish Ministry of Science and Innovation (BES-2017-079836). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses

  • Huang, Tianguang
  • Sun, Lin
  • Kang, Dongwei
  • Poongavanam, Vasanthanathan
  • Liu, Xinyong
  • Zhan, Peng
  • Menéndez-Arias, Luis
Recent coronavirus outbreaks of SARS-CoV-1 (2002–2003), MERS-CoV (since 2012), and SARS-CoV-2 (since the end of 2019) are examples of how viruses can damage health care and generate havoc all over the world. Coronavirus can spread quickly from person to person causing high morbidity and mortality. Unfortunately, the antiviral armamentarium is insufficient to fight these infections. In this chapter, we provide a detailed summary of the current situation in the development of drugs directed against pandemic human coronaviruses. Apart from the recently licensed remdesivir, other antiviral agents discussed in this review include molecules targeting viral components (e.g., RNA polymerase inhibitors, entry inhibitors, or protease inhibitors), compounds interfering with virus-host interactions, and drugs identified in large screening assays, effective against coronavirus replication, but with an uncertain mechanism of action., Financial support from the Key Project of NSFC for International Cooperation (No. 81420108027), and the Key Research and Development Project of Shandong Province (No. 2017CXGC1401, 2019JZZY021011, 2020SFXGFY08) are gratefully acknowledged. Work in Madrid was supported by grants of the Ministry of Science and Innovation of Spain (PID2019-104176RB-I00/AEI/10.13039/501100011033) and CSIC (2019AEP001). An institutional grant of the Fundación Ramón Areces to the CBMSO is also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Rapid, Highly Sensitive and Open-Access SARS-CoV-2 Detection Assay for Laboratory and Home Testing

  • Kellner, Max J.
  • Ross, James J.
  • Schnabl, Jakob
  • Dekens, Marcus P. S.
  • Heinen, Robert
  • Grishkovskaya, Irina
  • Bauer, Benedikt
  • Stadlmann, Johannes
  • Menéndez-Arias, Luis
  • Straw, Andrew D.
  • Fritsche-Polanz, Robert
  • Traugott, Marianna
  • Seitz, Tamara
  • Zoufaly, Alexander
  • Födinger, Manuela
  • Wenisch, Christoph
  • Zuber, Johannes
  • Vienna Covid-19 Diagnostics Initiative (VCDI)
  • Pauli, Andrea
  • Brennecke, Julius
RT-qPCR-based diagnostic tests play important roles in combating virus-caused pandemics such as Covid-19. However, their dependence on sophisticated equipment and the associated costs often limits their widespread use. Loop-mediated isothermal amplification after reverse transcription (RT-LAMP) is an alternative nucleic acid detection method that overcomes these limitations. Here, we present a rapid, robust, and sensitive RT-LAMP-based SARS-CoV-2 detection assay. Our 40-min procedure bypasses the RNA isolation step, is insensitive to carryover contamination, and uses a colorimetric readout that enables robust SARS-CoV-2 detection from various sample types. Based on this assay, we have increased sensitivity and scalability by adding a nucleic acid enrichment step (Bead-LAMP), developed a version for home testing (HomeDip-LAMP), and identified open-source RT-LAMP enzymes that can be produced in any molecular biology laboratory. On a dedicated website, rtlamp.org (DOI: 10.5281/zenodo.6033689), we provide detailed protocols and videos. Our optimized, general-purpose RT-LAMP assay is an important step toward population-scale SARS-CoV-2 testing., MK was supported by the Vienna Science and Technology Fund (WWTF) through project COV20-031 (to JZ) and a Cambridge Trust LMB Cambridge Scholarship. Research in the AP lab is supported by the Austrian Science Fund (START Projekt Y 1031-B28, SFB “RNA-Deco” F 80) and EMBO-YIP; research in the JB lab is supported by the European Research Council (ERC- 2015-CoG - 682181). The IMP receives generous institutional funding from Boehringer Ingelheim and the Austrian Research Promotion Agency (Headquarter grant FFG-852936); IMBA is generously supported by the Austrian Academy of Sciences. Work in the LM-A laboratory is supported by grant PID2019- 104176RB-I00/AEI/10.13039/501100011033 of the Spanish Ministry of Science and Innovation, and an institutional grant of the Fundación Ramón Areces., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity

  • Hassine, Ikbel Hadj
  • Ben M’hadheb, Manel
  • Menéndez-Arias, Luis
In RNA viruses, a small increase in their mutation rates can be sufficient to exceed their threshold of viability. Lethal mutagenesis is a therapeutic strategy based on the use of mutagens, driving viral populations to extinction. Extinction catastrophe can be experimentally induced by promutagenic nucleosides in cell culture models. The loss of HIV infectivity has been observed after passage in 5-hydroxydeoxycytidine or 5,6-dihydro-5-aza-2′-deoxycytidine while producing a two-fold increase in the viral mutation frequency. Among approved nucleoside analogs, experiments with polioviruses and other RNA viruses suggested that ribavirin can be mutagenic, although its mechanism of action is not clear. Favipiravir and molnupiravir exert an antiviral effect through lethal mutagenesis. Both drugs are broad-spectrum antiviral agents active against RNA viruses. Favipiravir incorporates into viral RNA, affecting the G→A and C→U transition rates. Molnupiravir (a prodrug of β-d-N4-hydroxycytidine) has been recently approved for the treatment of SARS-CoV-2 infection. Its triphosphate derivative can be incorporated into viral RNA and extended by the coronavirus RNA polymerase. Incorrect base pairing and inefficient extension by the polymerase promote mutagenesis by increasing the G→A and C→U transition frequencies. Despite having remarkable antiviral action and resilience to drug resistance, carcinogenic risks and genotoxicity are important concerns limiting their extended use in antiviral therapy., This research was funded by the Spanish Ministry of Science and Innovation (grant PID2019- 104176RB-I00/AEI/10.13039/501100011033), and an institutional grant of Fundación Ramón Areces (Madrid, Spain) to the CBMSO., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel RNase H Inhibitors Blocking RNA-directed Strand Displacement DNA Synthesis by HIV-1 Reverse Transcriptase

  • Martín-Alonso, Samara
  • Kang, Dongwei
  • Martínez del Río, Javier
  • Luczkowiak, Joanna
  • Frutos-Beltrán, Estrella
  • Zhang, Lina
  • Cheng, Xiqiang
  • Liu, Xinyong
  • Zhan, Peng
  • Menéndez-Arias, Luis
In retroviruses, strand displacement DNA-dependent DNA polymerization catalyzed by the viral reverse transcriptase (RT) is required to synthesize double-stranded proviral DNA. In addition, strand displacement during RNA-dependent DNA synthesis is critical to generate high-quality cDNA for use in molecular biology and biotechnology. In this work, we show that the loss of RNase H activity due to inactivating mutations in HIV-1 RT (e.g. D443N or E478Q) has no significant effect on strand displacement while copying DNA templates, but has a large impact on DNA polymerization in reactions carried out with RNA templates. Similar effects were observed with β-thujaplicinol and other RNase H active site inhibitors, including compounds with dual activity (i.e., characterized also as inhibitors of HIV-1 integrase and/or the RT DNA polymerase). Among them, dual inhibitors of HIV-1 RT DNA polymerase/RNase H activities, containing a 7-hydroxy-6-nitro-2H-chromen-2-one pharmacophore were found to be very potent and effective strand displacement inhibitors in RNA-dependent DNA polymerization reactions. These findings might be helpful in the development of transcriptomics technologies to obtain more uniform read coverages when copying long RNAs and for the construction of more representative libraries avoiding biases towards 5' and 3' ends, while providing valuable information for the development of novel antiretroviral agents., This work was supported in part by the Ministry of Science and Innovation of Spain through grant PID2019-104176RB-I00/AEI/10.13039/501100011033 awarded to L.M.-A. S.M.-A. is a predoctoral fellow of the Ministry of Science and Innovation of Spain (BES-2017-079836). J.M.R. is a predoctoral fellow of the Spanish Ministry of Universities (Formación Personal Universitario, FPU19/01653). An institutional grant of the Fundación Ramón Areces to the CBMSO is also acknowledged. The team at CBMSO is affiliated to the Global Virus Network. Work in Jinan was supported by the National Natural Science Foundation of China (81973181, 81903453), Science Foundation for Outstanding Young Scholars of Shandong Province (ZR2020JQ31), Science Foundation for Excellent Young Scholars of Shandong Province (ZR2020YQ61), Foreign cultural and educational experts project GXL20200015001, and the Shandong Provincial Key research and development project 2019JZZY021011., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Update and latest advances in antiretroviral therapy

  • Menéndez-Arias, Luis
  • Delgado, Rafael
Since the first cases of AIDS appeared in 1981, human immunodeficiency virus type 1 (HIV-1) infection has reached pandemic proportions. Forty years later, research has led to the approval of more than 30 antiretroviral drugs, while combination therapies have turned HIV-1 infection into a chronic, but manageable disease. Still, drug toxicity and acquired and transmitted drug resistance remain as major threats to therapy success. In this review, we provide an overview on currently available anti-HIV drugs and the latest developments in antiretroviral therapy, focused on new antiretroviral agents acting on known and unexploited antiviral targets, prevention therapies aimed to improve available drug combinations, and research on new long-acting therapies, particularly those involving novel drug candidates such as lenacapavir or islatravir., This work was supported in part by the Spanish Ministry of Science and Innovation (grant PID2019-104176RB-I00/AEI/10.13039/501100011033), and an institutional grant of Fundación Ramón Areces (Madrid, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Design, synthesis, and biological evaluation of novel double-winged galloyl derivatives as HIV-1 RNase H inhibitors

  • Zhang, Lina
  • Wei, Fenju
  • Borrego, David
  • Zhao, Fabao
  • Martínez del Río, Javier
  • Frutos-Beltrán, Estrella
  • Zhang, Jiwei
  • Xu, Shujing
  • López-Carrobles, Nerea
  • Gao, Shenghua
  • Kang, Dongwei
  • Pannecouque, Christophe
  • Clercq, Erik De
  • Liu, Xinyong
  • Menéndez-Arias, Luis
  • Zhan, Peng
Human immunodeficiency virus (HIV) reverse transcriptase (RT)-associated ribonuclease H (RNase H) remains as the only enzyme encoded within the viral genome not clinically validated as an antiviral target. We have previously reported that the galloyl derivative II-25 had RNase H inhibitory activity in enzymatic assays but showed weak antiviral activity in phenotypic assays due its large polarity and poor membrane permeability. In this report, we report on a series of II-25 derivatives, obtained by addition of different hydrophobic moieties ("the wings") at the C-2 and C-3 positions of the piperazine ring that showed improved RNase H inhibitory activity. Six compounds showed strong inhibitory activity and were found to be more potent than β-thujaplicinol in enzymatic assays. The most potent compound was IA-6 and exhibited the best inhibitory activity (IC50 = 0.067 ± 0.02 μM). IA-6 was around 11 and 30 times more potent than II-25 and β-thujaplicinol, respectively. Molecular modeling studies predict a strong hydrophobic interaction between the furylmethylaminyl group of IA-6 and the side chain of His539, explaining the potent HIV-1 RNase H inhibition. Unfortunately, none of the derivatives showed significant antiviral activity in cell culture. It is worth emphasizing that most of the obtained compounds show low cytotoxicity (CC50 > 20 μM), which confirms the significance of identifying galloyl derivatives as valuable leads for further optimization., We gratefully acknowledge financial support from the National Natural Science Foundation of China (NSFC Nos. 82173677, 81773574), the Key Project of NSFC for International Cooperation (No. 81420108027), the Shandong Provincial Key Research and Development Project (No. 2019JZZY021011), and the Science Foundation for Outstanding Young Scholars of Shandong Province (ZR2020JQ31). This work was supported in part by the Ministry of Science and Innovation of Spain through grant PID2019-104176RB-I00/AEI/10.13039/501100011 033 awarded to L.M.-A. J.M.R. is a predoctoral fellow of the Spanish Ministry of Universities (Formación de Profesorado Universitario, FPU19/01653). An institutional grant of the Fundación Ramón Areces to the CBMSO is also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Current medicinal chemistry strategies in the discovery of novel HIV-1 ribonuclease H inhibitors

  • Zhang, Lina
  • Wei, Fenju
  • Zhang, Jiwei
  • Liu, Chuanfeng
  • López-Carrobles, Nerea
  • Liu, Xinyong
  • Menéndez-Arias, Luis
  • Zhan, Peng
During HIV-1 genome replication, the viral reverse transcriptase-associated ribonuclease H (RT-associated RNase H) activity hydrolyzes the RNA strand of RNA/DNA heteroduplex intermediates. As of today, HIV-1 RNase H inhibitors (RHIs) remain at an investigational level, although none of them reached clinical trials. Therefore, RNase H remains as an attractive target for drug design and development. In this paper, we review the current status of medicinal chemistry strategies aimed at the discovery of novel RHIs, while discussing problems encountered in their characterization and further development, thereby providing an update on recent progress in the field., We gratefully acknowledge financial support from the National Natural Science Foundation of China (NSFC Nos. 82173677, 81773574), and the Science Foundation for Outstanding Young Scholars of Shandong Province (ZR2020JQ31). This work was supported in part by the Ministry of Science and Innovation of Spain through grant PID2019-104176RB-I00/AEI/10.13039/501100011033 awarded to L.M.-A. N.L.-C. is supported by a contract (PEJ‐2020‐AI/BMD‐19429) of the Youth Guarantee programme of the European Union, with the participation of the Comunidad de Madrid (Consejería de Educación, Universidades, Ciencia y Portavocía). An institutional grant of the Fundación Ramón Areces to the CBMSO is also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Emerging drug design strategies in anti-influenza drug discovery

  • Liu, Chuanfeng
  • Hu, Lide
  • Dong, Guanyu
  • Zhang, Ying
  • Ferreira da Silva-Júnior, Edeildo
  • Liu, Xinyong
  • Menéndez-Arias, Luis
  • Zhan, Peng
Influenza is an acute respiratory infection caused by influenza viruses (IFV), According to the World Health Organization (WHO), seasonal IFV epidemics result in approximately 3-5 million cases of severe illness, leading to about half a million deaths worldwide, along with severe economic losses and social burdens. Unfortunately, frequent mutations in IFV lead to a certain lag in vaccine development as well as resistance to existing antiviral drugs. Therefore, it is of great importance to develop anti-IFV drugs with high efficiency against wild-type and resistant strains, needed in the fight against current and future outbreaks caused by different IFV strains. In this review, we summarize general strategies used for the discovery and development of antiviral agents targeting multiple IFV strains (including those resistant to available drugs). Structure-based drug design, mechanism-based drug design, multivalent interaction-based drug design and drug repurposing are amongst the most relevant strategies that provide a framework for the development of antiviral drugs targeting IFV., We gratefully acknowledge financial support from the National Natural Science Foundation of China (NSFC No. 82173677), the Science Foundation for Outstanding Young Scholars of Shandong Province (ZR2020JQ31, China), and the China Postdoctoral Science Foundation (2022M711938). This work was supported in part by the Ministry of Science and Innovation of Spain through grant PID2019-104176RB-I00/AEI/10.13039/501100011033 awarded to Luis Menéndez-Arias-A. An institutional grant of the Fundación Ramón Areces to the CBMSO is also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting hepatitis B virus cccDNA levels: Recent progress in seeking small molecule drug candidates

  • Jin, Yu
  • Wang, Shuo
  • Xu, Shujing
  • Zhao, Shujie
  • Xu, Xiangrui
  • Poongavanam, Vasanthanathan
  • Menéndez-Arias, Luis
  • Zhan, Peng
  • Liu, Xinyong
Hepatitis B virus (HBV) infection is a major global health problem that puts people at high risk of death from cirrhosis and liver cancer. The presence of covalently closed circular DNA (cccDNA) in infected cells is considered to be the main obstacle to curing chronic hepatitis B. At present, the cccDNA cannot be completely eliminated by standard treatments. There is an urgent need to develop drugs or therapies that can reduce HBV cccDNA levels in infected cells. We summarize the discovery and optimization of small molecules that target cccDNA synthesis and degradation. These compounds are cccDNA synthesis inhibitors, cccDNA reducers, core protein allosteric modulators, ribonuclease H inhibitors, cccDNA transcriptional modulators, HBx inhibitors and other small molecules that reduce cccDNA levels., We gratefully acknowledge financial support from the National Natural Science Foundation of China (NSFC Nos. 82173677 and 81773574) and the Science Foundation for Outstanding Young Scholars of Shandong Province (ZR2020JQ31). This work was supported in part by the Ministry of Science and Innovation of Spain through grant PID2019-104176RB-I00/AEI/10.13039/501100011033 awarded to L.M.-A. An institutional grant of the Fundación Ramón Areces to the CBMSO is also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors

  • Song, Letian
  • Gao, Shenghua
  • Ye, Bing
  • Yang, Mianling
  • Yusen, Cheng
  • Kang, Dongwei
  • Yi, Fan
  • Sun, Jin-Peng
  • Menéndez-Arias, Luis
  • Neyts, Johan
  • Liu, Xinyong
  • Zhan, Peng
The main protease (Mpro) of SARS-CoV-2 is an attractive target in anti-COVID-19 therapy for its high conservation and major role in the virus life cycle. The covalent Mpro inhibitor nirmatrelvir (in combination with ritonavir, a pharmacokinetic enhancer) and the non-covalent inhibitor ensitrelvir have shown efficacy in clinical trials and have been approved for therapeutic use. Effective antiviral drugs are needed to fight the pandemic, while non-covalent Mpro inhibitors could be promising alternatives due to their high selectivity and favorable druggability. Numerous non-covalent Mpro inhibitors with desirable properties have been developed based on available crystal structures of Mpro. In this article, we describe medicinal chemistry strategies applied for the discovery and optimization of non-covalent Mpro inhibitors, followed by a general overview and critical analysis of the available information. Prospective viewpoints and insights into current strategies for the development of non-covalent Mpro inhibitors are also discussed., We gratefully acknowledge financial support from Major Basic Research Project of Shandong Provincial Natural Science Foundation (ZR2021ZD17, China), Science Foundation for Outstanding Young Scholars of Shandong Province (ZR2020JQ31, China), Foreign Cultural and Educational Experts Project (GXL20200015001, China), Guangdong Basic and Applied Basic Research Foundation (2021A1515110740, China), China Postdoctoral Science Foundation (2021M702003). This work was supported in part by the Ministry of Science and Innovation of Spain through grant PID2019-104176RB-I00/AEI/10.13039/501100011033 awarded to Luis Menéndez-Arias; An institutional grant of the Fundación Ramón Areces (Madrid, Spain) to the CBMSO is also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

An Update on Antiretroviral Therapy

  • Menéndez-Arias, Luis
  • Martín-Alonso, Samara
  • Frutos-Beltrán, Estrella
Human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS) still claim many lives across the world. However, research efforts during the last 40 years have led to the approval of over 30 antiretroviral drugs and the introduction of combination therapies that have turned HIV infection into a chronic but manageable disease. In this chapter, we provide an update on current available drugs and treatments, as well as future prospects towards reducing pill burden and developing long-acting drugs and novel antiretroviral therapies. In addition, we summarize efforts to cure HIV, including pharmaceutical strategies focused on the elimination of the virus., This work was supported by grants of the Ministry of Science and Innovation of Spain (BIO2016-76716-R (AEI/FEDER, UE) and PID2019-104176RB-I00/AEI/10.13039/501100011033 awarded to L.M.-A.), and CSIC (2019AEP001 awarded to L.M.-A.). S.M.-A. is a predoctoral fellow of the Ministry of Science and Innovation of Spain (BES-2017-079836). An institutional grant of the Fundación Ramón Areces to the CBMSO is also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Charge Engineering of the Nucleic Acid Binding Cleft of a Thermostable HIV-1 Reverse Transcriptase Reveals Key Interactions and a Novel Mechanism of RNase H Inactivation

  • Martínez del Río, Javier
  • López-Carrobles, Nerea
  • Mendieta-Moreno, Jesús I.
  • Herrera-Chacón, Óscar
  • Sánchez-Ibáñez, Adrián
  • Mendieta-Moreno, Jesús I.
  • Menéndez-Arias, Luis
Coupled with PCR, reverse transcriptases (RTs) have been widely used for RNA detection and gene expression analysis. Increased thermostability and nucleic acid binding affinity are desirable RT properties to improve yields and sensitivity of these applications. The effects of amino acid substitutions in the RT RNase H domain were tested in an engineered HIV-1 group O RT, containing mutations K358R/A359G/S360A and devoid of RNase H activity due to the presence of E478Q (O3MQ RT). Twenty mutant RTs with Lys or Arg at positions interacting with the template-primer (i.e., at positions 473–477, 499–502 and 505) were obtained and characterized. Most of them produced significant amounts of cDNA at 37, 50 and 65 °C, as determined in RT-PCR reactions. However, a big loss of activity was observed with mutants A477K/R, S499K/R, V502K/R and Y505K/R, particularly at 65 °C. Binding affinity experiments confirmed that residues 477, 502 and 505 were less tolerant to mutations. Amino acid substitutions Q500K and Q500R produced a slight increase of cDNA synthesis efficiency at 50 and 65 °C, without altering the K for model DNA/DNA and RNA/DNA heteroduplexes. Interestingly, molecular dynamics simulations predicted that those mutations inactivate the RNase H activity by altering the geometry of the catalytic site. Proof of this unexpected effect was obtained after introducing Q500K or Q500R in the wild-type HIV-1 RT and mutant K358R/A359G/S360A RT. Our results reveal a novel mechanism of RNase H inactivation that preserves RT DNA binding and polymerization efficiency without substituting RNase H active site residues., his work was supported in part by the Ministry of Science and Innovation of Spain through grants PID2019-104176RB-I00/AEI/MCI/10.13039/501100011033 awarded to L.M.-A, and PID2021-125604NB-I00/AEI/MCI/10.13039/501100011033 (supporting J.M. and J.I.M.-M.). J.M.R. is a predoctoral fellow of the Spanish Ministry of Universities (Formación de Profesorado Universitario, FPU19/01653). N.L.-C. was supported by a contract (PEJ-2020-AI/BMD-19429) of the Youth Guarantee programme of the European Union, with the participation of the Comunidad de Madrid (Consejería de Educación, Universidades, Ciencia y Portavocía). A.S.-I. received a short-term fellowship from CSIC (JAE-Intro program, JAEINT_20_00736/JAEINT_20_EX_0774). An institutional grant of Fundación Ramón Areces to the CBMSO is also acknowledged. The CBMSO has been certified since 2023 as Severo Ochoa Center of Excellence by AEI/MCI/10.13039/501100011033. The team at CBMSO is member of the Global Virus Network.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Recent advances in the molecular design and applications of proteolysis targeting chimera-based multi-specific antiviral modality

  • Zhou, Yang
  • Xua, Shujing
  • López-Carrobles, Nerea
  • Ding, Dang
  • Menéndez-Aria, Luis
  • Zhan, Peng
Viral infections represent a major threat to human health and the global economy; however, most of the currently available antiviral drugs are not fully effective in restricting viral replication and selecting for drug-resistant variants. Targeted protein degradation technologies are promising strategies to avoid or delay the emergence of drug resistance. Among the protein degradation-based multi-specific approaches, proteolysis targeting chimera (PROTAC) is the main strategy applied in the antiviral field. In this review we will introduce the elements and mechanisms of action used by PROTAC technology, as well as the advantages of PROTACs over available antiviral drugs. We also summarize the latest progress in the application of PROTACs in antiviral research, discuss existing challenges and look into future opportunities for antiviral drug discovery, We gratefully acknowledge financial support from the National Natural Science Foundation of China (NSFC No. 82173677) and the Science Foundation for Outstanding Young Scholars of Shandong Province (ZR2020JQ31). This work was supported, in part, by the Ministry of Science and Innovation of Spain through grant PID2019-104176RB-I00/AEI/10.13039/501100011033 awarded to L.M.-A. N.L.-C. is supported by a contract (PEJ2020-AI/BMD-19429) of the Youth Guarantee programme of the European Union with the participation of the Comunidad de Madrid (Consejería de Educación, Universidades, Ciencia y Portavocía). An institutional grant of the Fundación Ramón Areces to the CBMSO is also acknowledged. The team at CBMSO is affiliated to the Global Virus Network, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

A lyophilized open-source RT-LAMP assay for molecular diagnostics in resource-limited settings

  • Matl, Martin
  • Kellner, Max J.
  • Ansah, Felix
  • Grishkovskaya, Irina
  • Handler, Dominik
  • Heinen, Robert
  • Bauer, Benedikt
  • Menéndez-Arias, Luis
  • Auer, Thomas O.
  • Prieto-Godino, Lucia L.
  • Penninger, Josef M.
  • Vienna Covid-19 Detection Initiative (VCDI)
  • Awandare, Gordon A.
  • Brennecke, Julius
  • Pauli, Andrea
A critical bottleneck for equitable access to population-scale molecular diagnostics is the limited availability of rapid, inexpensive point-of-care tests especially in low- and middle-income countries. Here, we developed an open-source Reverse transcription loop-mediated isothermal amplification (RT-LAMP) molecular assay for the detection of respiratory RNA virus infections. It is based on non-proprietary enzymes, namely HIV-1 reverse transcriptase, Bst LF DNA polymerase and UDG BMTU thermolabile uracil DNA glycosylase. Formulated as liquid or lyophilized reaction mixtures, these reagents enable sensitive colorimetric detection of respiratory samples without the need for prior nucleic acid isolation. We evaluated our open-source lyophilized RT-LAMP assay on clinical samples with suspected COVID-19 infection, demonstrating high sensitivity and 100% specificity compared to the gold standard Reverse transcription quantitative polymerase chain reaction (RT-qPCR). Reaction performance was unaffected by prolonged storage of lyophilized reagents at ambient or elevated temperatures. As a proof of concept, we evaluated the robustness and ease-of-use of lyophilized RT-LAMP reaction mixes through independent laboratory testing of COVID-19 samples in Ghana. Overall, our open-source RT-LAMP assay provides a flexible and scalable point-of-care test that can be adapted for rapid detection of various pathogens in resource-limited settings., M.M. and M.J.K. were supported by the Vienna Science and Technology Fund (WWTF) through project COV20-031. This project received funding from the VW foundation (grant # 9A027) given to TReND in Africa, as well as funding from the "Mila Charitable Organisation". The IMP receives generous institutional funding from Boehringer Ingelheim and the Austrian Research Promotion Agency (Headquarter grant FFG852936), and IMBA is generously supported by the Austrian Academy of Sciences. Research in the lab of A.P. was supported by the Austrian Science Fund (START Projekt Y 1031-B28, SFB “RNA-Deco” F 80). Research in the lab of J.B. was supported by the European Research Council (ERC2015-CoG - 682181). F.A and G.A.A. were supported by a Science for Africa Foundation (SFA)/Wellcome Developing Excellence in Leadership Training and Science (DELTAS) in Africa grant (DEL-22-014: Awandare, G). Work in the L.M.-A. laboratory was supported by grant PID2019104176RBI00/AEI/10.13039/501100011033 of the Spanish Ministry of Science and Innovation, and an institutional grant of the Fundación Ramón Areces. The laboratory of J.M.P. at IMBA received funding from the Austrian Academy of Sciences, the Medical University of Vienna, the Swedish Research Council (2018- 05766), the T. von Zastrow foundation, and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101005026. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA., No